S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
Log in

TSE:BLUBELLUS Health News Headlines

C$15.82
-0.13 (-0.82 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
C$15.26
Now: C$15.82
C$16.68
50-Day Range
C$8.11
MA: C$12.90
C$15.95
52-Week Range
C$3.30
Now: C$15.82
C$16.68
Volume70,900 shs
Average Volume116,329 shs
Market CapitalizationC$951.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

BELLUS Health (TSE BLU) News Headlines

Source:
DateHeadline
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic CoughBELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
finance.yahoo.com - April 6 at 9:47 PM
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovationsBELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
finance.yahoo.com - March 25 at 2:23 PM
BRIEF-Bellus Health Inc - Bellus To Own 100% Of BLU-5937 And Related P2X3 Antagonists Intellectual Property With No Future Payments DueBRIEF-Bellus Health Inc - Bellus To Own 100% Of BLU-5937 And Related P2X3 Antagonists Intellectual Property With No Future Payments Due
www.reuters.com - March 23 at 8:35 AM
BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovationsBELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
finance.yahoo.com - March 23 at 8:35 AM
BRIEF-Bellus Health Says Completed Enrollment In Phase 2 Relief Trial Of Blu-5937 For Refractory Chronic CoughBRIEF-Bellus Health Says Completed Enrollment In Phase 2 Relief Trial Of Blu-5937 For Refractory Chronic Cough
www.reuters.com - March 19 at 11:11 PM
IIROC Trading Halt - BLUIIROC Trading Halt - BLU
finance.yahoo.com - March 19 at 1:10 PM
IIROC Trade Resumption - BLUIIROC Trade Resumption - BLU
finance.yahoo.com - March 19 at 1:10 PM
Bellus Health completes enrollment in mid-stage BLU-5937 trialBellus Health completes enrollment in mid-stage BLU-5937 trial
seekingalpha.com - March 19 at 8:09 AM
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic CoughBELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
finance.yahoo.com - March 19 at 8:09 AM
Have Insiders Been Buying BELLUS Health Inc. (TSE:BLU) Shares This Year?Have Insiders Been Buying BELLUS Health Inc. (TSE:BLU) Shares This Year?
finance.yahoo.com - February 21 at 7:16 AM
BELLUS Health Inc.BELLUS Health Inc.
www.barrons.com - February 15 at 10:40 PM
Should You Worry About BELLUS Health Inc.'s (TSE:BLU) CEO Salary Level?Should You Worry About BELLUS Health Inc.'s (TSE:BLU) CEO Salary Level?
finance.yahoo.com - January 16 at 8:55 AM
Hedge Funds Welcomed BELLUS Health Inc. (BLU) With Open ArmsHedge Funds Welcomed BELLUS Health Inc. (BLU) With Open Arms
finance.yahoo.com - December 13 at 1:55 PM
Does BELLUS Health Inc. (TSE:BLU) Have A Particularly Volatile Share Price?Does BELLUS Health Inc. (TSE:BLU) Have A Particularly Volatile Share Price?
finance.yahoo.com - September 19 at 4:51 PM
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common SharesBELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
finance.yahoo.com - September 18 at 7:29 AM
Buy Bellus Health Before It Hits The NasdaqBuy Bellus Health Before It Hits The Nasdaq
seekingalpha.com - September 15 at 5:19 PM
Birch Pollen Allergy Drug Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2025Birch Pollen Allergy Drug Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2025
www.marketwatch.com - September 11 at 8:36 AM
BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United StatesBELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
finance.yahoo.com - September 9 at 12:48 PM
US IPO Weekly Recap: The fall IPO market is looking up as 10 companies launch in a 1-IPO weekUS IPO Weekly Recap: The fall IPO market is looking up as 10 companies launch in a 1-IPO week
www.nasdaq.com - September 6 at 11:18 PM
BELLUS Health Seeks $60 Million U.S. IPOBELLUS Health Seeks $60 Million U.S. IPO
seekingalpha.com - September 5 at 9:24 AM
Canadian biotech BELLUS Health prices upsized $70 million US IPO at $7.10Canadian biotech BELLUS Health prices upsized $70 million US IPO at $7.10
www.nasdaq.com - September 5 at 9:24 AM
BRIEF-BELLUS Health Announces The Launch Of A $60 Mln Public Offering Of Common Shares In Canada And U.S.BRIEF-BELLUS Health Announces The Launch Of A $60 Mln Public Offering Of Common Shares In Canada And U.S.
www.msn.com - September 3 at 9:42 PM
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical OfficerBELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
finance.yahoo.com - August 26 at 11:33 AM
Read This Before Selling BELLUS Health Inc. (TSE:BLU) SharesRead This Before Selling BELLUS Health Inc. (TSE:BLU) Shares
finance.yahoo.com - August 22 at 9:59 AM
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019
finance.yahoo.com - August 8 at 12:34 PM
BRIEF-Bellus Health Says First Patient Enrolled In Mid-Stage Study Of Chronic Cough TreatmentBRIEF-Bellus Health Says First Patient Enrolled In Mid-Stage Study Of Chronic Cough Treatment
www.msn.com - July 31 at 12:32 PM
Mid-stage study underway for Bellus Health candidate for chronic coughMid-stage study underway for Bellus Health candidate for chronic cough
seekingalpha.com - July 30 at 11:16 AM
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic PruritusBELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus
finance.yahoo.com - July 30 at 11:16 AM
What Kind Of Shareholder Owns Most BELLUS Health Inc. (TSE:BLU) Stock?What Kind Of Shareholder Owns Most BELLUS Health Inc. (TSE:BLU) Stock?
finance.yahoo.com - July 16 at 4:22 PM
BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough TreatmentBELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment
finance.yahoo.com - July 15 at 11:01 AM
Director Franklin Berger buys as Bellus Health stock blasts higherDirector Franklin Berger buys as Bellus Health stock blasts higher
www.theglobeandmail.com - June 29 at 10:29 AM
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International ConferenceBELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
finance.yahoo.com - May 21 at 4:36 PM
BELLUS Health to Present at Three Upcoming Healthcare Investor ConferencesBELLUS Health to Present at Three Upcoming Healthcare Investor Conferences
finance.yahoo.com - May 15 at 11:03 AM
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019
finance.yahoo.com - May 9 at 11:11 AM
Bellus: 1Q Earnings SnapshotBellus: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 11:11 AM
How Much Did BELLUS Health Inc.'s (TSE:BLU) CEO Pocket Last Year?How Much Did BELLUS Health Inc.'s (TSE:BLU) CEO Pocket Last Year?
finance.yahoo.com - April 25 at 4:30 PM
BELLUS Health to Present at Two Upcoming Healthcare Investor ConferencesBELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
finance.yahoo.com - April 4 at 11:24 AM
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough PatientsBELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients
finance.yahoo.com - April 3 at 11:41 AM
Is BELLUS Health’s (TSE:BLU) Share Price Gain Of 244% Well Earned?Is BELLUS Health’s (TSE:BLU) Share Price Gain Of 244% Well Earned?
finance.yahoo.com - March 18 at 4:47 PM
BELLUS Health Presents 2018 Highlights and 2019 Corporate PlanBELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
finance.yahoo.com - February 21 at 12:45 PM
Should You Be Concerned About BELLUS Health Inc.’s (TSE:BLU) Historical Volatility?Should You Be Concerned About BELLUS Health Inc.’s (TSE:BLU) Historical Volatility?
finance.yahoo.com - February 6 at 4:21 PM
BELLUS Health Announces Payment of $134,149 to Thallion CVR HoldersBELLUS Health Announces Payment of $134,149 to Thallion CVR Holders
finance.yahoo.com - December 28 at 10:43 AM
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic CoughBELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough
finance.yahoo.com - December 18 at 10:45 AM
This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Special Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel